Strategic Focus Aerium Therapeutics is concentrating on antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic threats, indicating opportunities to discuss collaborations, licensing, or co-development for next-generation antivirals and rapid response programs.

Recent Partnerships The company has secured Series A funding from Omega Funds and F-Prime Capital and is actively developing three monoclonal antibodies, signaling investor-backed growth and potential for co-investment discussions, pilot programs, or grant-enabled initiatives.

Global Footprint With bases in Boston and Switzerland, Aerium’s international presence supports multi-regional engagement, regulatory strategy alignment, and potential for cross-border manufacturing partnerships, clinical trial sites, or distribution alliances.

Early Revenue Current revenue is under one million, suggesting a lean operation with room for strategic partnerships in manufacturing, CRO/CDMO services, or collaboration deals that accelerate scale-up and market access.

Tech & Compliance Stack Use of Cloudflare, Microsoft 365, DocuSign, and DNS services indicates robust digital infrastructure; this can facilitate discussions around secure data sharing, collaboration tooling for joint programs, and streamlined contracting or IP licensing processes.